Skip to main content
IMRN
NASDAQ Life Sciences

Immuron Reports Double-Digit Q3 Sales Growth, Driven by Strong Australian and Canadian Performance

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$0.805
Mkt Cap
$6.781M
52W Low
$0.677
52W High
$2.39
52W Position info
19% above low
Off High info
66% below high
Rel. Volume info
2.2× avg
Market data snapshot near publication time

IMRN sits 19% above its 52-week low of $0.677 on elevated volume (2.2× avg).

Summary

Immuron Ltd announced unaudited third-quarter sales of AUD$1.5 million, representing a 16% increase year-over-year, with strong growth in Australia and Canada.


Key Events · Earnings and Guidance · IMRN

  • Strong Q3 Sales Growth

    Immuron reported unaudited global Q3 sales of AUD$1.5 million, a 16% increase compared to the prior comparative period.

  • Key Regional Performance

    Australian Q3 sales grew 15% to AUD$0.9 million, while Canadian Q3 sales increased over 100% on the prior comparative period, driven by new listings and promotions.

  • Year-to-Date Sales Up

    Year-to-date sales through March 2026 reached AUD$5.7 million, up 7% from the prior comparative period.


Analysis · IMRN · Life Sciences

Immuron Ltd announced unaudited third-quarter sales of AUD$1.5 million, marking a significant 16% increase compared to the prior comparative period. This growth was primarily fueled by strong performance in Australia, where sales rose 15% to AUD$0.9 million, and Canada, which saw sales more than double. For a company of Immuron's size, consistent double-digit sales growth is a positive indicator of operational execution and market penetration for its Travelan® product, providing a strong signal of business momentum.

How filings like this one have moved

In the 30 days to Sep 14, 2026, 29.9% of the 1591 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.24%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, IMRN was trading at $0.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.8M. The 52-week trading range was $0.68 to $2.39. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

IMRN - Latest Insights

IMRN
Aug 28, 2026, 8:00 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $1.16
Real-time Price: $1.38 info
Change: +$0.220 (+19%) info
Market Cap: $12.034M info
IMRN
Jul 27, 2026, 8:00 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $1.11
Real-time Price: $1.38 info
Change: +$0.2726 (+25%) info
Market Cap: $12.034M info
IMRN
Jul 20, 2026, 8:00 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $1.26
Real-time Price: $1.38 info
Change: +$0.120 (+10%) info
Market Cap: $12.034M info
IMRN
Jul 16, 2026, 6:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.19
Real-time Price: $1.38 info
Change: +$0.190 (+16%) info
Market Cap: $12.034M info
IMRN
Jul 06, 2026, 8:00 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $1.10
Real-time Price: $1.38 info
Change: +$0.280 (+25%) info
Market Cap: $12.034M info